Endothelial function, variables of fibrinolysis and coagulation in smokers and healthy controls

Haemostasis

Volumn 30, Issue 3, 2000, Pages 149-158

  Enderle, Markus D ^a   Pfohl, M ^b   Kellermann, N ^b   Haering, H U ^b   Hoffmeister, H M ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

Coagulation; Endothelial dysfunction; Fibrinolysis; Intima media thickness; Smoking

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRINOGEN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; SMOKING; VASODILATATION;

EID: 0033808058     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022537     Document Type: Article

References (37)

1. Ross R: Mechanisms of disease -Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340: 115-126.
2. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B: Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989;79: 287-291.
3. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1994;93:50-55.
4. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robbins J, et al: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-2155.
5. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, et al: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334:150-154.
6. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474.
7. Salonen JT, Salonen R: Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993;87:1156-1165.
8. Geroulakos G, O'Gorman D, Nicolaides A, Sheridan D, Elkeles R, Shaper AG: Carotid intima-media thickness: Correlation with the British Regional Heart Study risk score. J Intern Med 1994;235:431-433.
9. Bots ML, Hofman A, Grobbee DE: Common carotid intima-media thickness and lower extremity arterial atherosclerosis. The Rotterdam Study. Arterioscler Thromb 1994;14:1885-1891.
10. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22.
11. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L: Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995;91:2520-2527.
12. Hoffmeister HM, Jur M, Ruf M, Heller W, Seipel L: Inhibitors of the hemostasis and related systems in patients with acute myocardial infarction or unstable angina pectoris. Fibrinolysis 1995;9:104-108.
13. Tousoulis D, Bosinakou E, Tentolouris C, Apostolopoulos T, Copshari C, Kyriakides M, et al: t-Plasminogen activator and von Willebrand factor in patients with unstable angina. Int J Cardiol 1996;54: 89-92.
14. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; ii:3-9.
15. Caputo M, Mantini G, Floriani I, Ciceri M, Noseda A, Bonomo L: Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease. Eur Heart J 1996;17:1329-1336.
16. Smith FB, Lee AJ, Rumley A, Fowkes FG, Lowe GD: Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995;115:35-43.
17. Gris JC, Schved JF, Feugeas O, Aguilar Martinez P, Arnaud A, Sanchez N, et al: Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men. Thromb Haemost 1990;64:516-520.
18. Juhan Vague I: Haemostatic parameters and vascular risk. Atherosclerosis 1996;124(suppl):S49-S55.
19. Eliasson M, Asplund K, Evrin PE, Lundblad D: Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995;113:41-53.
20. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK: Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995;91:284-290.
21. Enderle MD, Benda N, Schmuelling RM, Haering HU, Pfohl M: Preserved endothelial function compared with healthy subjects in IDDM patients, but not in NIDDM patients. Diabetes Care 1998;21: 271-277.
22. Enderle MD, Schroeder S, Ossen R, Meisner C, Baumbach A, Haering HU, et al: Comparison of peripheral endothelial dysfunction and intima media thickness in patients with suspected coronary artery disease. Heart 1998;80:349-354.
23. Hrubez Z, Cederlof R, Friberg Z: Background of angina pectoris: Social and environmental factors in relation to smoking. Am J Epidemiol 1976;103:16-29.
24. Higman DJ, Strachan AM, Powell JT: Reversibility of smoking-induced endothelial dysfunction. Br J Surg 1994;81:977-978.
25. Zhu BQ, Parmley WW: Hemodynamic and vascular effects of active and passive smoking. Am Heart J 1995;130:1270-1275.
26. Jacobs MC, Lenders JW, Kapma JA, Smits P, Thien T: Effect of chronic smoking on endothelium-dependent vascular relaxation in humans. Clin Sci (Colch) 1993;85:51-55.
27. Anderson EA, Mark AL: Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation 1989;79:93-100.
28. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340: 1111-1115.
29. Markus RA, Azen SP, Hodis HN, Mack WJ: Influence of lifestyle modification on atherosclerotic progression determined by ultrasonographic change in the common carotid intima media thickness. Am J Clin Nutr 1997;65:1000-1004.
30. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Selwyn AP, Ganz P: Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-1650.
31. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-250.
32. Wilhelmsen L, Svardsudd K, Korsan Bengtsen K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505.
33. Eliasson M, Evrin PE, Lundblad D, Asplund K, Ranby M: Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. A population study. Fibrinolysis 1993;7:316-323.
34. Kristensen SD, Falk E: Pathophysiology of acute ischemic syndromes: Recent progress. Fibrinolysis 1997; 11:105-108.
35. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J: Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vase Biol 1995;15:893-902.
36. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE: Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343: 940-943.
37. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.